In the present study, we used the same approach to determine whether modifications of specific lysine residues of H3 that are targets of CBP and/or PCAF (P300/CBP-associated factor), HATs that were implicated in HD previously [18,19,20], influence HD pathology. The gene discussed is CREBBP; the disease is Huntington disease.